Bank of New York Mellon Corp Has $33.80 Million Stock Holdings in Qiagen N.V. $QGEN

Bank of New York Mellon Corp decreased its position in Qiagen N.V. (NYSE:QGEN) by 6.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 844,167 shares of the company’s stock after selling 53,679 shares during the quarter. Bank of New York Mellon Corp’s holdings in Qiagen were worth $33,800,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of QGEN. Danske Bank A S bought a new stake in shares of Qiagen during the 3rd quarter worth $36,000. Manchester Capital Management LLC bought a new position in Qiagen in the 4th quarter worth $42,000. Global Retirement Partners LLC raised its holdings in Qiagen by 279.9% in the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after acquiring an additional 851 shares during the period. Allworth Financial LP lifted its position in Qiagen by 23.2% during the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock worth $61,000 after acquiring an additional 256 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new position in Qiagen during the 3rd quarter worth $64,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Citigroup reaffirmed a “hold” rating on shares of Qiagen in a research report on Monday, May 18th. TD Cowen reissued a “hold” rating on shares of Qiagen in a research report on Wednesday, July 15th. Weiss Ratings downgraded Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 29th. Robert W. Baird set a $43.00 target price on Qiagen and gave the company an “outperform” rating in a report on Wednesday, April 29th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $43.00 price target on shares of Qiagen in a research report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Qiagen currently has an average rating of “Hold” and an average price target of $43.34.

Qiagen Stock Up 0.0%

NYSE QGEN opened at $41.38 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. The firm has a 50-day simple moving average of $38.12 and a 200 day simple moving average of $42.09. Qiagen N.V. has a twelve month low of $32.53 and a twelve month high of $57.81. The stock has a market cap of $8.53 billion, a PE ratio of 21.61, a PEG ratio of 4.13 and a beta of 0.64.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.54. The firm had revenue of $492.32 million for the quarter, compared to analyst estimates of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same period in the previous year, the company posted $0.56 earnings per share. On average, research analysts forecast that Qiagen N.V. will post 2.43 EPS for the current year.

Qiagen Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were given a dividend of $0.35 per share. This is a boost from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 90.0%. The ex-dividend date was Tuesday, July 7th. Qiagen’s dividend payout ratio (DPR) is presently 18.32%.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.